These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16361278)

  • 1. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.
    Diekmann F; Campistol JM
    Nephrol Dial Transplant; 2006 Mar; 21(3):562-8. PubMed ID: 16361278
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria.
    Saurina A; Campistol JM; Piera C; Diekmann F; Campos B; Campos N; de las Cuevas X; Oppenheimer F
    Nephrol Dial Transplant; 2006 Feb; 21(2):488-93. PubMed ID: 16280369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
    Audard V
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S395-9. PubMed ID: 20129452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
    Diekmann F; Budde K; Slowinski T; Oppenheimer F; Fritsche L; Neumayer HH; Campistol JM
    Transpl Int; 2008 Feb; 21(2):152-5. PubMed ID: 18005087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
    Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus attenuates chronic allograft nephropathy in an experimental rat kidney transplantation model.
    Savikko J; von Willebrand E
    Transplant Proc; 2006 Oct; 38(8):2699-700. PubMed ID: 17098043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E; Legendre C
    Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A; Campistol JM; Lario S; Oppenheimer F; Diekmann F
    Transplant Proc; 2007 Sep; 39(7):2138-41. PubMed ID: 17889117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
    Sánchez Fructuoso A; Ruiz San Millán JC; Calvo N; Rodrigo E; Moreno MA; Cotorruelo J; Conesa J; Gómez-Alamillo C; Arias M; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
    Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus conversion experience in a single center.
    Wang HH; Huang JY; Chu SH; Chiang YJ; Liu KL; Lai PC
    Transplant Proc; 2008 Sep; 40(7):2209-10. PubMed ID: 18790194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R
    Transplantation; 2009 Apr; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic allograft nephropathy--a clinical syndrome: early detection and the potential role of proliferation signal inhibitors.
    Campistol JM; Boletis IN; Dantal J; de Fijter JW; Hertig A; Neumayer HH; Oyen O; Pascual J; Pohanka E; Ruiz JC; Scolari MP; Stefoni S; Serón D; Sparacino V; Arns W; Chapman JR
    Clin Transplant; 2009; 23(6):769-77. PubMed ID: 19719730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency.
    Kamar N; Frimat L; Blancho G; Wolff P; Delahousse M; Rostaing L
    Transpl Int; 2007 Feb; 20(2):128-34. PubMed ID: 17239020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of switching from calcineurin inhibitor to sirolimus on the incidence of skin cancers in kidney transplant recipients.
    McQuillan RF; O'Seaghdha CM; Bagatto A; Manusamy M; Errakiah N; Sinnott C; O'Kelly P; Murphy GM; Conlon PJ
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):330-1. PubMed ID: 18631208
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.